Background. Outpatient parenteral antimicrobial therapy (OPAT) patients have high rates of adverse drug events, emergency visits, and readmissions. Understanding correlates of mortality during and after OPAT may clarify opportunities to enhance care and meaningfully interpret the clinical profile of patients receiving OPAT.
Methods. We analyzed a cohort of patients enrolled in our OPAT program from 2015 to 2018. Patients were followed to death or December 31, 2018, whichever came first. Using Linkplus, we linked patients to North Carolina death records by name, birth date, and sex. We performed a probabilistic linkage and reviewed any nondeterministic matches. Clinical and demographic data were extracted by chart review. Cause of death was determined by first cause in the state death data, as indexed by ICD-10 code. Mortality rates were tabulated at 90 days and 1 year after treatment start. Predictors of 1-year mortality were assessed by multivariable logistic regression and adjusted for age, sex, Staphylococcus aureus infection, early antibiotic stop, and readmission.
Results. Among 729 OPAT courses in the study, the median age was 54 (interquartile range, IQR 44-65) and 60% were male. Seventy-seven deaths occurred during the period at a median 272 days (IQR 89-462), including 7 during OPAT (figure). Mortality at 90 days and 1 year was 3.1% (19 of 617 eligible OPAT courses) and 7.1% (31 of 408), respectively. 90-day mortality was equally due to infection (37%) and cancer (37%), whereas 1-year death was most commonly due to infection (32%). The most commonly reported causes of death at any time during the period were cancer (25%), infection (19%) and cardiovascular disease (17%). Each year increase in age was associated with a 5% relative increase in odds of 1-year death (odds ratio, OR, 1.05, 95% CI 1.02-1.08), and readmission was associated with risk of 1-year death (adjusted OR 7.78, CI 3.46-17.50).
Conclusion. In this large OPAT cohort, 90-day mortality was 3% and 1-year mortality was 7%. Readmission during OPAT was a strong predictor of 1-year death. Strategies to decrease 1-year mortality may include mitigating readmissions or allocating resources after readmission. The prevalence of cancer-related death suggests an opportunity for OPAT providers and oncologists to collaborate in care of high-risk patients.
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No reported disclosures. Background. Infections are common in terminally ill patients, and although antibiotics are frequently prescribed, their benefit for symptom relief is not clear. Antimicrobials at the end of life (EOL) increase the risk of antimicrobial resistance and Clostridium difficile infection. Very few studies have described the risks and benefits of antimicrobials in patients at EOL. Here, we describe a retrospective chart review of antimicrobial use at EOL.
Use of Antimicrobials at the End of Life (EOL): A Retrospective Cohort Study Analyzing Providers' Reasons for Prescribing Antimicrobials at the EOL, Their Benefits and Adverse Effects
Methods. We reviewed electronic medical records of patients admitted in a palliative care unit of a tertiary care hospital between 2017 and 2018 and assessed antimicrobial use in the last 14 days of life. The analysis excluded neutropenic patients. Differences in demographics and symptom control between patients who did or did not receive antibiotics (AB+ or AB−) were analyzed using chi-square analyses; P-values were computed using Mann-Whitney tests.
Results. Of a total of 133 patients included, 89 (67%) received antimicrobials (AB+); however, the role of antibiotics was documented in only 12% of patients. The AB− and AB+ groups were similar with respect to demographics, including sex, and Charleston Comorbidity Index except for age (table) . Documented infections were similar between AB− and AB+ groups, except urinary tract infections. No statistically significant differences were noted in documented symptoms including pain, dyspnea, fever, lethargy, and alteration of mental state or length of stay (LOS).
Conclusion. Our study did not show differences in frequencies of documented symptoms with use of antimicrobials at EOL. These results indicate that the risks of antimicrobial use may outweigh potential benefits and their use should be a part of goals of care discussions at EOL.
Background. Antimicrobial stewardship interventions to decrease testing and treatment of asymptomatic bacteriuria (ASB) have primarily focused on inpatient clinicians, however emergency medicine (EM) clinicians also test and treat ASB. We identified testing attributable to EM clinicians and patient-level factors associated with EM treatment of ASB.
Methods. Between November 2017 and March 2019, data were abstracted from medical records of adult non-ICU medical patients at 43 Michigan hospitals admitted through the Emergency Department (ED) with a positive urine culture (Ucx) collected on day 1 or 2 of hospitalization. Exclusions included pregnancy, urologic surgery or abnormality, immune-compromise, severe sepsis, or concomitant infection. ASB was defined as a positive Ucx without signs or symptoms of a urinary tract infection (UTI). The treatment group included patients receiving ≥1 antibiotic dose ordered by an EM clinician. Patient factors associated with ASB treatment by EM clinicians vs. no treatment were evaluated using logistic generalized estimating equation models.
Results. Of 1,778 patients with ASB, 74.7% (N = 1328) had a Ucx ordered by an EM clinician (Figure 1) , and 74.4% (N = 1323) were treated with antibiotics ( Figure 2) . Of those treated for ASB, 64.3% (851/1328) had the first dose ordered by an EM clinician ( Figure 2) . Patient variables associated with EM treatment included nonambulatory status, incontinence, presence of a urinary catheter, acutely altered mental status (AMS), leukocytosis, and positive urinalysis (Table 1) . When EM initiated treatment, most patients (80%) remained on antibiotics for ≥3 days (Figure 3) , with a median treatment duration of 6 days [IQR 4-9].
Conclusion. Among patients with ASB admitted through the ED with a Ucx collected on day 1 or 2 of hospitalization, most were treated with antibiotics. The majority of testing and initial treatment for ASB was by EM clinicians. The strongest predictors of EM treatment of ASB were positive urinalysis and AMS. Once started by EM, patients often received a full course for UTI. Given the burden of ASB testing and treatment, expanding stewardship into the ED is critical and should start with addressing interpretation of urinalyses in patients without specific urinary symptoms.
